Voyager Therapeutics (FRA:VT6) EV-to-Revenue : 0.89 (As of Jun. 09, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Voyager Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Voyager Therapeutics's enterprise value is €97.7 Mil. Voyager Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was €109.3 Mil. Therefore, Voyager Therapeutics's EV-to-Revenue for today is 0.89.

The historical rank and industry rank for Voyager Therapeutics's EV-to-Revenue or its related term are showing as below:

FRA:VT6' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.07 Med: 4.13 Max: 77.84
Current: 0.89

During the past 11 years, the highest EV-to-Revenue of Voyager Therapeutics was 77.84. The lowest was 0.07. And the median was 4.13.

FRA:VT6's EV-to-Revenue is ranked better than
88.14% of 1037 companies
in the Biotechnology industry
Industry Median: 7.86 vs FRA:VT6: 0.89

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-09), Voyager Therapeutics's stock price is €7.57. Voyager Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €2.15. Therefore, Voyager Therapeutics's PS Ratio for today is 3.52.

Voyager Therapeutics EV-to-Revenue Historical Data

The historical data trend for Voyager Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Voyager Therapeutics EV-to-Revenue Chart

Voyager Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

2.56

0.78

0.38

3.42

0.64

Voyager Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-Revenue	Get a 7-Day Free Trial															0.44	1.28	0.68	0.64	1.29

Competitive Comparison of Voyager Therapeutics's EV-to-Revenue

For the Biotechnology subindustry, Voyager Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Voyager Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Voyager Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Voyager Therapeutics's EV-to-Revenue falls into.

Voyager Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Voyager Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	97.678	/	109.343
	=	0.89

Voyager Therapeutics's current Enterprise Value is €97.7 Mil.
Voyager Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €109.3 Mil.

Voyager Therapeutics (FRA:VT6) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Voyager Therapeutics's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	7.57	/	2.153
	=	3.52

Voyager Therapeutics's share price for today is €7.57.
Voyager Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.15.

Voyager Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Voyager Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Voyager Therapeutics (FRA:VT6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Voyager Therapeutics Inc (FRA:VT6) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

VYGR:USA VT6:Germany

Address

64 Sidney Street, Cambridge, MA, USA, 02139

Website

https://www.voyagertherapeutics.com

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. The company operates in a single segment of developing and commercializing gene therapies.

Voyager Therapeutics (FRA:VT6) Headlines

No Headlines